

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 July 2025 (31.07.2025)



(10) International Publication Number
WO 2025/160082 A1

(51) International Patent Classification:

C07K 14/575 (2006.01) *A61P 3/06* (2006.01)
A61K 38/00 (2006.01) *A61P 3/10* (2006.01)
A61K 38/22 (2006.01) *A61P 9/12* (2006.01)
A61P 3/04 (2006.01) *A61P 43/00* (2006.01)

(21) International Application Number:

PCT/US2025/012446

(22) International Filing Date:

21 January 2025 (21.01.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/624,205 23 January 2024 (23.01.2024) US

(71) Applicant: **VIKING THERAPEUTICS, INC.** [US/US];

9920 Pacific Heights Blvd., Suite 350, San Diego, California 92121 (US).

(72) Inventors: **LIAN, Brian**; c/o Viking Therapeutics, Inc.,

9920 Pacific Heights Blvd., Suite 350, San Diego, California 92121 (US). **BARKER, Geoffrey E.**; c/o Viking Therapeutics, Inc., 9920 Pacific Heights Blvd., Suite 350, San Diego, California 92121 (US). **ENUGURTHI, Brahmachary**; c/o Viking Therapeutics, Inc., 9920 Pacific Heights Blvd., Suite 350, San Diego, California 92121 (US). **STEVENS, Erland**; c/o Viking Therapeutics, Inc., 9920 Pacific Heights Blvd., Suite 350, San Diego, California 92121 (US). **BARNES, Maureen**; c/o Viking Therapeutics,

Inc., 9920 Pacific Heights Blvd., Suite 350, San Diego, California 92121 (US). **YAGIZ, Kader**; c/o Viking Therapeutics, Inc., 9920 Pacific Heights Blvd., Suite 350, San Diego, California 92121 (US).

(74) Agent: **ACHTSAM, Jessica L.**; Knobbe Martens Olson &

Bear LLP, 2040 Main Street, Fourteenth Floor, Irvine, California 92614 (US).

(81) Designated States (*unless otherwise indicated, for every*

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every*

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: AMYLIN ANALOGS




FIG. 2

(57) **Abstract:** The present invention encompasses polypeptides of Formula (I), and pharmaceutically acceptable salts thereof that are effective as amylin analogs. Amylin analogs of Formula (I) find use in the treatment of metabolic disorders or metabolic syndrome in a subject.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*